Posts

Posted on

Aurora Mobile Launches Hong Kong Edition of JVerification to Streamline and Innovate Cross-Border Login and Verification

SHENZHEN, China, April 16, 2025 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced the official launch of the Hong Kong edition of its verification service, JVerification (“JVerification (HK)”). As digital transformation continues to accelerate globally, the demand for seamless and secure cross-border services has become a top priority for developers. With this latest release, Aurora Mobile provides developers with a more efficient and secure verification solution to help businesses expand into the Hong Kong market.

JVerification (HK)
: A Next-Level Cross-Border Login and Verification Solution

Based on Aurora Mobile’s proven verification services, JVerification (HK) is specifically tailored for the Hong Kong market. With an upgraded SDK, it now fully supports two major scenarios:

  1. Login and verification for Hong Kong mobile numbers within Hong Kong
  2. Login and verification for Hong Kong mobile numbers within Mainland China

By streamlining the user verification process, JVerification (HK) enables fast and secure one-click login and verification, providing a seamless user experience with no complicated steps.

Technical Strength and Reliability: Aurora Mobile’s Core Advantages

JVerification (HK) leverages China Mobile’s SDK to provide robust technical support in Hong Kong. China Mobile’s well-established network infrastructure and expert local team offer a rock-solid foundation for service reliability and performance.

  • Quick Response: Even during peak traffic periods, login requests are processed quickly, ensuring a smooth login experience.
  • Security and Reliability: JVerification (HK) upholds strict technical standards and employs robust data protection mechanisms to ensure user privacy and data integrity.

The First Step in Expanding Cross-Border Verification

The launch of JVerification (HK) marks Aurora Mobile’s first major step into cross-border verification services. Looking ahead, the Company plans to expand service scenarios to enable “Mainland China mobile number logins in Hong Kong,” with the aim of refining its cross-border verification services and meeting the diverse business needs of developers.

This expansion will support:

  • Mainland Chinese developers going global: Helping mainland Chinese developers tap into the Hong Kong market as a gateway for overseas expansion and to enhance their global competitiveness.
  • Hong Kong and overseas developers: Providing Hong Kong and global developers with a more efficient verification tool to make local apps more competitive.

Full-Spectrum Technical Support for Developers

Aurora Mobile is committed to a developer-first approach and provides a professional technical support team that is available to assist developers with any issues during the integration process. From consulting to implementation, Aurora Mobile offers developers comprehensive support to ensure a smooth service launch.

About Aurora Mobile Limited

Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services in China. Since its inception, Aurora Mobile has focused on providing stable and efficient messaging services to enterprises and has grown to be a leading mobile messaging service provider with its first-mover advantage. With the increasing demand for customer reach and marketing growth, Aurora Mobile has developed forward-looking solutions such as Cloud Messaging and Cloud Marketing to help enterprises achieve omnichannel customer reach and interaction, as well as artificial intelligence and big data-driven marketing technology solutions to help enterprises’ digital transformation.

For more information, please visit https://ir.jiguang.cn/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

Aurora Mobile Limited
E-mail: [email protected]

Christensen

In China
Ms. Xiaoyan Su
Phone: +86-10-5900-1548
E-mail: [email protected]

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]



Posted on

EXPANDED CLASS PERIOD: Fluence Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FLNC

PR Newswire


SAN DIEGO
, April 16, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Fluence Energy, Inc. (NASDAQ: FLNC) Class A common stock between October 28, 2021 and February 10, 2025, inclusive (the “Class Period”), have until May 12, 2025 to seek appointment as lead plaintiff of the Fluence Energy class action lawsuit. Captioned Kramer v. Fluence Energy, Inc., No. 25-cv-00634 (E.D. Va.), the Fluence Energy class action lawsuit charges Fluence Energy and certain of Fluence Energy’s top current and former executives with violations of the Securities Exchange Act of 1934. A previously filed complaint is captioned Abramov v. Fluence Energy, Inc., No. 25-cv-00444 (E.D. Va.).

If you suffered substantial losses and wish to serve as lead plaintiff of the Fluence Energy class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-fluence-energy-inc-class-action-lawsuit-flnc.html
 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Fluence Energy is a global provider of energy storage products and services and digital applications for renewable energy and storage.

The Fluence Energy class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) a material portion of Fluence Energy’s energy storage products suffered from defective design, installation, operational, and/or maintenance issues; (ii) Fluence Energy had repeatedly failed to adequately address known product defects and installation errors, and/or failed to honor outstanding warranty obligations Fluence Energy owed to its customers; (iii) the efficacy and safety of Fluence Energy’s energy storage products and Fluence Energy’s ability to timely deliver projects to its customers’ satisfaction had been materially overstated; (iv) as a result, Fluence Energy’s adjusted EBITDA, adjusted gross profit, and adjusted gross profit margins were artificially inflated throughout the Class Period; and (v) consequently, Fluence Energy was exposed to material undisclosed risks of reputational and financial harm, including through loss of business from current and/or prospective clients.

On December 20, 2023Energy Storage News published an article revealing that Fluence Energy’s work on its Diablo project had suffered from a “litany of ‘defects, deficiencies, and failures.'” The article detailed several alleged defects and chronic failures that plagued the Diablo project, including, inter alia, that: (i) Fluence Energy’s project control system responded slowly or inaccurately, causing California’s system operator to temporarily remove the project from the service markets; (ii) Fluence Energy’s proprietary systems failed to function properly, requiring project owners to resort to alternative technologies not designed for that purpose, resulting in costly inefficiencies; (iii) Fluence Energy’s inverters failed 27 times within a short 1-month period, just 2 months after project delivery; and (iv) the occurrence of 2 arc flashes created the risk of serious harm and injury. Beyond these significant defects, the article revealed that Fluence Energy had delivered the Diablo project approximately eight months after it was contractually due and repeatedly failed to timely address and resolve related warranty claims. On this news, the price of Fluence Energy Class A common stock fell more than 15%.

Then, on February 22, 2024, Blue Orca Capital published a research report revealing that Fluence Energy had prematurely sold its sixth-generation technology before the design of the technology had been completed. The report disclosed that this failure had contributed to the operational mishaps that had occurred at Fluence Energy’s installed projects, including the Diablo project. In addition, the research report revealed that a Siemens’ affiliate, Siemens Energy Inc., had filed a lawsuit against Fluence Energy for fraud, misrepresentation, and a host of engineering and design failures with respect to a project located in Antioch, California. On this news, the price of Fluence Energy Class A common stock fell more than 13%.

Thereafter, on November 25, 2024, Fluence Energy reported financial results for its fourth fiscal quarter and full year 2024 (“4Q24 Release”). The 4Q24 Release issued annual revenue guidance for fiscal 2025 of approximately $3.6 billion to $4.4 billion, representing year-over-year growth of approximately 48% at the midpoint of the range. The 4Q24 Release revealed that only 65% of Fluence Energy’s fiscal 2025 revenue guidance (at the midpoint) was “covered by the Company’s current backlog,” indicating that Fluence Energy did not have sufficient work contracted and would need to secure additional new orders to meet its revenue targets. On this news, the price of Fluence Energy Class A common stock fell approximately 22% over a two-day trading period.

Finally, on February 10, 2025, Fluence Energy reported financial results for its first fiscal quarter of 2025 (“1Q25 Release”). The 1Q25 Release revealed that Fluence Energy was reducing its fiscal 2025 revenue guidance from a range of $3.6 billion to $4.4 billion to a range of $3.1 billion to $3.7 billion, representing a reduction of approximately $600 million at the midpoint. The 1Q25 Release further revealed that the guidance revision was the result of “‘customer driven delays'” in executing outstanding contracts and “‘competitive pressures.'” The 1Q25 Release further revealed that quarterly revenue of $187 million significantly missed consensus estimates of $363 million by nearly 48%, representing a significant departure from the already muted expectations set by Fluence Energy’s “back-end loaded” revenue cadence disclosed during the prior quarter. On this news, the price of Fluence Energy Class A common stock fell more than 52% over a three-day trading period.

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Fluence Energy Class A common stock during the class period to seek appointment as lead plaintiff in the Fluence Energy class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Fluence Energy class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Fluence Energy class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fluence Energy class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/expanded-class-period-fluence-energy-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit—flnc-302429985.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

Yum China Announces Disclosure under Hong Kong Stock Exchange Rules in Relation to a Possible Quarterly Dividend

PR Newswire


SHANGHAI
, April 16, 2025 /PRNewswire/ — Yum China Holdings, Inc. (NYSE: YUMC and HKEX: 9987, “Yum China” or the “Company”) today announced, in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “HKEX”) which require advance notice of board meetings at which a dividend is expected to be declared, that its board of directors (the “Board”) will consider the declaration and payment of a quarterly dividend (the “Dividend”). If the Board decides to proceed, the declaration will be adopted by Board resolution on or around April 30, 2025 (Beijing/Hong Kong Time) and will be promptly disclosed by the Company.

The Company makes available through the Investor Relations section of its internet website at http://ir.yumchina.com its filings with the HKEX as soon as reasonably practicable after electronically filing such materials with the HKEX. These filings may also be obtained by visiting the HKEX’s website at http://www.hkex.com.hk. 

As no Board resolution in relation to the Dividend has been adopted as of the date of this press release, there is no assurance that the Dividend will be declared.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “expect,” “expectation,” “believe,” “anticipate,” “may,” “could,” “intend,” “belief,” “plan,” “estimate,” “target,” “predict,” “project,” “likely,” “will,” “continue,” “should,” “forecast,” “outlook” or similar terminology. These statements are based on current estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable under the circumstances, but there can be no assurance that such estimates and assumptions will prove to be correct. Forward-looking statements are not guarantees of performance and are inherently subject to known and unknown risks and uncertainties that are difficult to predict and could cause our actual results or events to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or assumptions will be achieved. The forward-looking statements included in this press release are only made as of the date of this press release, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. Numerous factors could cause our actual results or events to differ materially from those expressed or implied by forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. You should consult our filings with the Securities and Exchange Commission (including the information set forth under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q) for additional detail about factors that could affect our financial and other results.

About Yum China Holdings, Inc. 

Yum China is the largest restaurant company in China with a mission to make every life taste beautiful. The Company operates over 16,000 restaurants under six brands across around 2,200 cities in China. KFC and Pizza Hut are the leading brands in the quick-service and casual dining restaurant spaces in China, respectively. In addition, Yum China has also partnered with Lavazza to develop the Lavazza coffee concept in China. Little Sheep and Huang Ji Huang specialize in Chinese cuisine. Taco Bell offers innovative Mexican-inspired food. Yum China has a world-class, digitalized supply chain which includes an extensive network of logistics centers nationwide and an in-house supply chain management system. Its strong digital capabilities and loyalty program enable the Company to reach customers faster and serve them better. Yum China is a Fortune 500 company with the vision to be the world’s most innovative pioneer in the restaurant industry. For more information, please visit http://ir.yumchina.com. 

Investor Relations Contact
Tel: +86 21 2407 7556
E-mail: [email protected] 

Media Contact
Tel: +86 21 2407 8288 / +852 2267 5807
E-mail: [email protected] 

 

Cision View original content:https://www.prnewswire.com/news-releases/yum-china-announces-disclosure-under-hong-kong-stock-exchange-rules-in-relation-to-a-possible-quarterly-dividend-302430111.html

SOURCE Yum China Holdings, Inc.

Posted on

Coty Announces ESG Rating Upgrades from MSCI and Sustainalytics

Coty Announces ESG Rating Upgrades from MSCI and Sustainalytics

MSCI ESG Rating has been upgraded to A from BB

Sustainalytics ESG rating now at low risk and 3rd among Household Product companies

NEW YORK–(BUSINESS WIRE)–Coty Inc. (NYSE: COTY) (Paris: COTY) (“Coty” or “the Company”) one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, is proud to announce improvements in its Environmental, Social, and Governance (ESG) ratings from both MSCI and Sustainalytics.

This achievement underscores Coty’s dedication to advancing sustainability across all aspects of its business.

Coty’s MSCI ESG Rating has been upgraded to A from BB. This improvement reflects enhanced performance across several key ESG areas, including:

  • Packaging Material & Waste
  • Raw Material Sourcing
  • Chemical Safety
  • Corporate Governance

Coty’s MSCI Carbon Footprint score remains at the maximum level, demonstrating the Company’s ongoing commitment to minimizing its environmental impact.

Coty improved its Sustainalytics ESG Risk Rating, moving from 23.9 (medium risk) to 18.1 (low risk). This progress places Coty as the lead amongst global beauty companies and 3rd out of 104 in Household Products companies as rated by Sustainalytics.

The Company’s Sustainalytics improvement is attributed to advancements in seven key areas:

  • Environmental & Social Impact of Products and Services
  • Land Use and Biodiversity
  • Water Use
  • Human Capital
  • Product Governance
  • Data Privacy and Security
  • Corporate Governance

The upgrades follow Coty’s strong progress in the 2024 CDP Climate Change disclosure, with the company scoring A-, an increase from B in 2023. Coty’s FY24 Sustainability Report highlighted key achievements including surpassing 2030 Scope 1 and 2 emissions targets with an 82% reduction since 2019, cutting air freight emissions by 65%, and using 100% renewable electricity in its owned factories and distribution centers.

About Coty Inc.

Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in over 120 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.

Investor Relations

Olga Levinzon

+1 212 389-7733

[email protected]

Media

Antonia Werther

+31 621 394495

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Sustainability Environment Environmental, Social and Governance (ESG) Climate Change Professional Services Luxury Cosmetics Retail

MEDIA:

Logo
Logo
Posted on

Conditional Issuance of Shares

INSIDE INFORMATION

REGULATED INFORMATION

Conditional Issuance of Shares

Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate number of ordinary shares that can be sold and issued under the Company’s ATM to 5,662,694 (the “ATM Shares”), which includes 662,694 shares that are still available from the conditional issuance of shares under the ATM decided upon on December 22, 2022.

Pursuant to the existing sales agreement entered into by the Company on December 22, 2022, ATM Shares may be sold from time to time at a sales price per ATM Share equal to prevailing USD market prices of the Nyxoah ordinary share on the Nasdaq Global Market at the time of the sale.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities.

Contacts:

Nyxoah

John Landry, CFO
[email protected]

Attachment



Posted on

BW LPG Limited – Repurchase of own shares

BW LPG Limited – Repurchase of own shares

SINGAPORE–(BUSINESS WIRE)–
BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”) has purchased a total of 316,437 of its own ordinary shares from 8 April 2025 to 11 April 2025 at an average price of USD 8.63 per share. The shares were purchased in accordance with the share buy-back program announced on 8 April 2025. Under the share buyback program, the Company may purchase up to 3 million ordinary shares for a maximum amount of USD 20 million.

After these transactions, BW LPG holds 7,939,347 of its ordinary shares, representing 4.98% of the total issued shares. The shares purchased will be held as Treasury Shares.

An overview of all transactions made under the program that have been carried out during the above-mentioned period is attached to this report and available at www.newsweb.no.

About BW LPG

BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating a fleet of more than 50 Very Large Gas Carriers (VLGCs) with a total carrying capacity of over 4 million CBM. With five decades of operating experience in LPG shipping, an in-house LPG trading division and a growing presence in LPG terminal infrastructure and distribution, BW LPG offers an integrated, flexible, and reliable service to customers along the LPG value chain. Delivering energy for a better world – more information about BW LPG can be found at https://www.bwlpg.com.

BW LPG is associated with BW Group, a leading global maritime company involved in shipping, floating infrastructure, deepwater oil & gas production, and new sustainable technologies. Founded in 1955 by Sir YK Pao, BW controls a fleet of over 450 vessels transporting oil, gas and dry commodities, with its 200 LNG and LPG ships constituting the largest gas fleet in the world. In the renewables space, the group has investments in solar, wind, batteries, and water treatment.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

For further information, please contact

Kristian Sørensen

Chief Executive Officer

Samantha Xu

Chief Financial Officer

[email protected]

KEYWORDS: North America United States Asia Pacific Singapore Southeast Asia

INDUSTRY KEYWORDS: Oil/Gas Energy Maritime Logistics/Supply Chain Management Transport

MEDIA:

Logo
Logo
Posted on

BW LPG Limited – Update on BW LPG’s Product Services Q1 2025 Segment Performance

BW LPG Limited – Update on BW LPG’s Product Services Q1 2025 Segment Performance

SINGAPORE–(BUSINESS WIRE)–
BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”) today provides an update on its Product Services’ (“BW Product Services”) Q1 2025 segment performance.

For the quarter ended 31 March 2025, BW Product Services achieved a realised gain of USD 33 million from our cargo and freight operations. After accounting for the unrealised mark-to-market change of negative USD 36 million from our open cargo contracts and hedging transactions, we ended the quarter with a gross trading result of approximately minus USD 3 million.

After general and administrative expenses and income taxes, BW Product Services reported an estimated result of approximately minus USD 12 million for the quarter.

The average Value-At-Risk (VAR) for the quarter was approximately USD 5 million.

BW LPG will release its Q1 2025 financial report on 20 May 2025.

Says Kristian Sørensen, Chief Executive Officer, “We are pleased to report a continued strong realisation of USD 33 million from our cargo deliveries and trades in the first quarter of 2025. We focus on delivering a positive realised trading result which is the ultimate driver for BW Product Services’ dividend capacity, although some volatility should be anticipated as we charter through these unprecedented markets.”

About BW LPG

BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating a fleet of more than 50 Very Large Gas Carriers (VLGCs) with a total carrying capacity of over 4 million CBM. With five decades of operating experience in LPG shipping, an in-house LPG trading division and a growing presence in LPG terminal infrastructure and distribution, BW LPG offers an integrated, flexible, and reliable service to customers along the LPG value chain. Delivering energy for a better world – more information about BW LPG can be found at https://www.bwlpg.com.

BW LPG is associated with BW Group, a leading global maritime company involved in shipping, floating infrastructure, deepwater oil & gas production, and new sustainable technologies. Founded in 1955 by Sir YK Pao, BW controls a fleet of over 450 vessels transporting oil, gas and dry commodities, with its 200 LNG and LPG ships constituting the largest gas fleet in the world. In the renewables space, the group has investments in solar, wind, batteries, and water treatment.

For further information, please contact:

Kristian Sørensen

Chief Executive Officer

Samantha Xu

Chief Financial Officer

E-mail: [email protected]

KEYWORDS: North America United States Asia Pacific Singapore Southeast Asia

INDUSTRY KEYWORDS: Energy Transport Logistics/Supply Chain Management Oil/Gas

MEDIA:

Logo
Logo
Posted on

ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025

ASML reports €7.7 billion total net sales and €2.4 billion net income in Q1 2025

2025 total net sales expected to be between €30 billion and €35 billion

VELDHOVEN, the Netherlands, April 16, 2025 – Today, ASML Holding NV (ASML) has published its 2025 first-quarter results.

  • Q1 total net sales of €7.7 billion, gross margin of 54.0%, net income of €2.4 billion
  • Quarterly net bookings in Q1 of €3.9 billion2 of which €1.2 billion is EUV
  • ASML expects Q2 2025 total net sales between €7.2 billion and €7.7 billion, and a gross margin between 50% and 53%3
  • ASML continues to expect 2025 total net sales to be between €30 billion and €35 billion, with a gross margin between 51% and 53%
(Figures in millions of euros unless otherwise indicated) Q4 2024
  		Q1 2025
Total net sales 9,263
  		7,742
…of which Installed Base Management sales1 2,147
  		2,001
New lithography systems sold (units) 119
  		73
Used lithography systems sold (units) 13
  		4
Net bookings2 7,088
  		3,936
Gross profit 4,790
  		4,180
Gross margin (%) 51.7
  		54.0
Net income 2,693
  		2,355
EPS (basic; in euros) 6.85
  		6.00
End-quarter cash and cash equivalents and short-term investments 12,741
  		9,104

(1) Installed Base Management sales equals our net service and field option sales.
(2) Net bookings include all system sales orders and inflation-related adjustments, for which written authorizations have been accepted.
(3) The bandwidth for Q2 2025 gross margin guidance is larger than usual, given the uncertainty around the impact of tariffs.
Numbers have been rounded for readers’ convenience. A complete summary of US GAAP Consolidated Statements of Operations is published on www.asml.com.

CEO statement and outlook

“Our first-quarter total net sales came in at €7.7 billion, in line with our guidance. The gross margin was 54.0%, above guidance, driven by a favorable EUV product mix and the achievement of performance milestones. In the first quarter, we shipped our fifth High NA system, and we now have these systems at three customers.

“Our conversations so far with customers support our expectation that 2025 and 2026 will be growth years. However, the recent tariff announcements have increased uncertainty in the macro environment and the situation will remain dynamic for a while. As previously shared, artificial intelligence continues to be the primary growth driver in our industry. It has created a shift in the market dynamics that benefits some customers more than others, contributing to both upside potential and downside risks as reflected in our 2025 revenue range.

“We expect second-quarter total net sales between €7.2 billion and €7.7 billion, with a gross margin between 50% and 53%3. We expect R&D costs of around €1.2 billion and SG&A costs of around €300 million. As we previously communicated, we expect total net sales for the year between €30 billion and €35 billion, with a gross margin between 51% and 53%, subject to the uncertainties mentioned earlier,” said ASML President and Chief Executive Officer Christophe Fouquet.

Update dividend and share buyback program

ASML intends to declare a total dividend for the year 2024 of €6.40 per ordinary share, which is a 4.9% increase compared to 2023.

Recognizing the three interim dividends of €1.52 per ordinary share paid in 2024 and 2025, this leads to a final dividend proposal to the Annual General Meeting of €1.84 per ordinary share.

In the first quarter, we purchased around €2.7 billion worth of shares under the current 2022-2025 share buyback program.

Details of the share buyback program as well as transactions pursuant thereto, and details of the dividend are published on ASML’s website (www.asml.com/investors).

Media Relations contacts Investor Relations contacts
Monique Mols +31 6 5284 4418 Jim Kavanagh +31 40 268 3938
Willem van Ewijk +31 6 2744 1187 Pete Convertito +1 203 919 1714
Karen Lo +886 9 397 88635 Peter Cheang +886 3 659 6771

Quarterly video interview and investor call

With this press release, ASML is publishing a video interview in which CEO Christophe Fouquet and CFO Roger Dassen discuss the 2025 first-quarter and outlook for 2025. This video and the video transcript can be viewed on www.asml.com shortly after the publication of this press release.

An investor call for both investors and the media will be hosted by CEO Christophe Fouquet and CFO Roger Dassen on April 16, 2025 at 15:00 Central European Time / 09:00 US Eastern Time. Details can be found on our website.

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.


  

US GAAP Reporting

ASML’s primary accounting standard for quarterly earnings releases and annual reports is US GAAP, the accounting principles generally accepted in the United States of America. Quarterly summary US GAAP consolidated statements of operations, consolidated statements of cash flows and consolidated balance sheets are available on www.asml.com.

The consolidated balance sheets of ASML Holding N.V. as of March 30, 2025, the related consolidated statements of operations and consolidated statements of cash flows for the quarter and three months ended March 30, 2025 as presented in this press release are unaudited.

Regulated information

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Forward Looking Statements

This document and related discussions contain statements that are forward-looking within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements with respect to plans, strategies, expected trends, including trends in the semiconductor industry and end markets and business environment trends, expected growth in the semiconductor industry by 2030, our expectation that AI will be the key driver for the industry and the expected impact of AI demand on our business and results, our expectation that lithography will remain at the heart of customer innovation, expected demand, bookings, outlook of market segments, outlook and expected financial results including expected results for Q2 2025, including net sales, Installed Base Management sales, gross margin, R&D costs, SG&A costs, outlook for full year 2025, including expected full year 2025 total net sales, gross margin, estimated annualized effective tax rate and expected growth in IBM sales, the expectation that 2025 and 2026 will be growth years, statements made at our 2024 Investor Day, including revenue and gross margin opportunity for 2030, statements with respect to the recent US tariff announcements and the expected impact of such tariffs on our business and results, our expectation to continue to return significant amounts of cash to shareholders through growing dividends and share buybacks, statements with respect to our share buyback program, and statements with respect to dividends, statements with respect to expected performance and capabilities of our systems and customer plans, statements with respect to our ESG strategy and other non- historical statements. You can generally identify these statements by the use of words like “may”, “expect”, “will”, “could”, “should”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “intend”, “continue”, “target”, “future”, “progress”, “goal”, “model”, “opportunity” and variations of these words or comparable words. These statements are not historical facts, but rather are based on current expectations, estimates, assumptions, plans and projections about our business and our future financial results and readers should not place undue reliance on them. Forward- looking statements do not guarantee future performance and involve a number of substantial known and unknown risks and uncertainties. These risks and uncertainties include, without limitation, risks relating to customer demand, semiconductor equipment industry capacity, worldwide demand for semiconductors and semiconductor manufacturing capacity, lithography tool utilization and semiconductor inventory levels, general trends and consumer confidence in the semiconductor industry, the impact of general economic conditions, including the impact of the current macroeconomic environment on the semiconductor industry, uncertainty around a market recovery including the timing thereof, the ultimate impact of AI on our industry and business, the impact of inflation, interest rates, wars and geopolitical developments, the impact of pandemics, the performance of our systems, the success of technology advances and the pace of new product development and customer acceptance of and demand for new products, our production capacity and ability to adjust capacity to meet demand, supply chain capacity, timely availability of parts and components, raw materials, critical manufacturing equipment and qualified employees, our ability to produce systems to meet demand, the number and timing of systems ordered, shipped and recognized in revenue, risks relating to fluctuations in net bookings and our ability to convert bookings into sales, the risk of order cancellation or push outs and restrictions on shipments of ordered systems under export controls, risks relating to the trade environment, import/export and national security regulations and orders and their impact on us, including the impact of changes in export regulations and the impact of such regulations on our ability to obtain necessary licenses and to sell our systems and provide services to certain customers, the impact of the recent tariff announcements, exchange rate fluctuations, changes in tax rates, available liquidity and free cash flow and liquidity requirements, our ability to refinance our indebtedness, available cash and distributable reserves for, and other factors impacting, dividend payments and share repurchases, the number of shares that we repurchase under our share repurchase program, our ability to enforce patents and protect intellectual property rights and the outcome of intellectual property disputes and litigation, our ability to meet ESG goals and execute our ESG strategy, other factors that may impact ASML’s business or financial results, and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F for the year ended December 31, 2024 and other filings with and submissions to the US Securities and Exchange Commission. These forward-looking statements are made only as of the date of this document. We undertake no obligation to update any forward-looking statements after the date of this report or to conform such statements to actual results or revised expectations, except as required by law.

Attachments



Posted on

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

  • Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors
  • Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors
  • Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors
  • Two new members would join the board of Directors

MARSEILLE, France–(BUSINESS WIRE)–
Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to one with a CEO/board of directors. This transformation is part of the Company’s strategic plan to simplify and align its governance with international standards.

It will be proposed that shareholders appoint, as members of the board of Directors, the following individuals:

  • Mrs. Irina Staatz Granzer;
  • Mr. Jonathan Dickinson;
  • Mrs. Véronique Chabernaud;
  • Mrs. Pascale Boissel;
  • Bpifrance Participations, represented by Mr. Olivier Martinez;
  • Mrs. Sally Bennett;
  • Mr. Christian Itin; and
  • Mr. Marty J. Duvall.

Mr. Itin and Duvall would be new members as would be Mr. Dickinson, currently Chairman of the Executive board. The other directors are currently members of the Supervisory board.

If shareholders approve this governance change and the proposed board of Directors composition the future board of Directors would appoint Mrs. Irina Staatz-Granzer as its Chairwoman and Mr. Jonathan Dickinson as Chief Executive Officer during its first meeting after the Annual General Meeting.

If shareholders do not approve the governance change, it would be proposed to renew the mandate of, or appoint, depending on each case, the individuals listed above as members of the Supervisory board. Mrs. Irina Staatz-Granzer would remain its Chairwoman. The Executive board composition would remain unchanged, and Mr. Jonathan Dickinson would remain its Chairman.

As part of the proposed changes, two current Supervisory board members would not join the future board of Directors, Mr. Gilles Brisson and Mr. Jean-Yves Blay.

Mr. Hervé Brailly, co-founder of Innate Pharma, has made the considered decision not to seek re-appointment to the board of Directors.

“I am pleased that Innate is proposing transformation to a board of Directors structure, which will be submitted for shareholder approval. This step marks an important milestone in aligning our governance model with international standards and reflects our commitment to implementing investor feedback to ensure continued progress and adoption of best practices,” said Jonathan Dickinson, Chairman of the Executive board of Innate Pharma

“On behalf of the Supervisory board, I would like to extend my sincere thanks to Mr. Hervé Brailly, Mr. Gilles Brisson and Mr. Jean-Yves Blay for their dedication and valuable support throughout their tenure. In particular, Mr. Hervé Brailly has been instrumental in leading and supporting the company’s development since inception, and we are very grateful to him for his seasoned guidance and commitment,” commented Irina Staatz-Granzer, Chairwoman of the Supervisory board of Innate Pharma. “The evolution to a board of Directors marks not only a structural evolution, but also a renewed commitment to strong governance and long-term value creation. In this context, we are also pleased to propose the appointment of two new international members, each bringing deep and strong experience in the biotech and pharmaceutical industry. Their knowledge and perspective will be key assets as we enter this next chapter.”

Information about the new members to join the board of Directors

Mr. Marty J. Duvall

Global Builder of Companies and Brands in Oncology

Marty J. Duvall is an accomplished and passionate biotech executive based in the U.S., with over 35 years of experience building companies in the pharma and biotechnology industry, focused in specialty therapeutics.

Mr. Duvall’s big pharma experience includes global oncology leadership positions at Aventis and Merck. His biotech experience includes C-level contributions to company builds leading to value-creating transactions at MGI Pharma, Abraxis Bioscience, and ARIAD, where he worked to build a footprint across the US, Europe and Asia.

His CEO experience includes both public companies (Tocagen and Oncopeptides) as well as private companies (Angiex) and includes a successful IPO and follow-on financings under his leadership.

With an oncology focus over the last three decades, Marty J. Duvall has helped launch and drive many successful therapeutics that have benefited patients with a wide range of cancers, including breast, lung, prostate, gastric, head and neck, brain, melanoma, myelodysplastic syndrome, leukemia, and multiple myeloma.

Dr Christian Itin

CEO of Autolus

Christian Itin is a very seasoned biotechnology company leader with more than 25 years of industry experience. He currently serves as CEO of Autolus Therapeutics (Nasdaq: AUTL). He built Autolus into a fully integrated biopharmaceutical, company commercializing its first CART cell therapy product Aucatzyl® approved by the US FDA in November 2024.

Previously, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company acquired in March 2012 by Amgen, Inc. for USD 1.2 billion. Micromet developed the first T-cell engaging antibody Blincyto®, now standard of care for the treatment of B-cell acute leukaemia.

From 2016 to 2019 Christian was on the board of Kuros Biosciences (SIX: KURN) serving as chairman from 2016 to 2018. Prior to Kuros he served as executive chairman of Cytos Biotechnology Ltd from 2012 to 2016 until its merger with Kuros Biosurgery, forming Kuros Biosciences. Kuros developed and is commercializing MagnetOS™, a synthetic bone graft replacing bone allo-or xenografts. Christian also served as non-executive director on the board of Kymab, Ltd, a privately held UK company from 2012 until its acquisition by Sanofi in 2021 for a USD 1.1 billion upfront payment plus additional milestones.

He has a diploma in biology and holds a PhD in cell biology summa cum laude from the University of Basel, Switzerland and performed post-doctoral research at the Biocenter of Basel University and at Stanford University School of Medicine, CA, USA.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

[email protected]

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

[email protected]

KEYWORDS: Europe United States North America France Maryland

INDUSTRY KEYWORDS: General Health Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France–(BUSINESS WIRE)–
Regulatory News: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille.

The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bulletin. It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.

Documents and information relating to this meeting will be made available to shareholders in accordance with current regulations, and will also be available in the Investors section of the Company’s website.

****

The annual general meeting will also be broadcasted live and available at the following link:

Innate Pharma 2025 annual general meeting

A guided tour of the Company’s laboratories is organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour at this link: company laboratories tour registration form.

****

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by zero hour Paris time, will be able to participate.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the voting or proxy form.

Written questions from shareholders must be received four business days prior to the AGM at the latest (by e-mail to [email protected]).

Shareholders can also obtain the documents and information in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to [email protected].

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

[email protected]

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

[email protected]

KEYWORDS: Europe United States North America France Maryland

INDUSTRY KEYWORDS: Oncology Health Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo